Ligand to Participate in Four Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:

• JMP Securities Life Sciences Conference in New York City. Presentation on Wednesday, June 24, 2015 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). Matt Foehr, President and COO will present for Ligand.
• 2nd Annual Roth Healthcare Day in London. Conference takes place on Wednesday, June 24, 2015 with no group presentation. John Higgins, CEO will attend for Ligand.
• Cantor Fitzgerald Inaugural “From Bench to Bedside” Healthcare Conference in New York City. Presentation on Wednesday, July 8, 2015 at 4:45 p.m. Eastern time (1:45 p.m. Pacific time). John Higgins, CEO will present for Ligand.
• CJS Securities 15th Annual Summer New Ideas Conference in White Plains, NY. Conference takes place on Tuesday, July 14, 2015 with no webcast presentation. Matt Foehr, President and COO will present for Ligand.

A live webcast of the JMP and Cantor presentations will be available on Ligand’s website at www.ligand.com. A replay of the presentations will be archived on the website for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including; Novartis, Amgen, Merck, Pfizer, Baxter International and Eli Lilly.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150617006429/en/

Ligand Pharmaceuticals Incorporated
Todd Pettingill
(858) 550-7500
[email protected]
or
LHA
Bruce Voss
(310) 691-7100
[email protected]

Source: Ligand Pharmaceuticals Incorporated

You May Also Be Interested In

• Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
• TraceLink MINT Transaction Volume in 2026 Surpasses Full-Year 2025 Volume by 183% as Customers Expand Digital Supply Chain Collaboration
• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight